AstraZeneca AZN announced that the FDA has accepted a regulatory filing seeking to expand the use of its blockbuster rare disease drug, Ultomiris (ravulizumab), for immunoglobulin A nephropathy (IgAN), a rare progressive kidney disease.
The FDA has granted the filing priority review, shortening the review period by four months. A final decision is expected in the fourth quarter of 2026.
If approved, Ultomiris will be the first C5 complement inhibitor available for IgAN. The drug is currently approved in the United States, Europe and Japan across four indications. These include atypical haemolytic uraemic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) and paroxysmal nocturnal haemoglobinuria (PNH).
The FDA filing is supported by interim data from the late-stage I CAN study, which showed that treatment with the drug for 34 weeks led to a statistically significant and clinically meaningful reduction in proteinuria (protein in urine). Per AstraZeneca, Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo.
A potential approval would broaden the commercial potential of the drug, which is currently one of AstraZeneca’s key growth drivers. In first-quarter 2026, Ultomiris generated $1.27 billion in sales, up 18% year over year, driven by strong demand across approved indications, geographic expansion and continued patient conversion from Soliris.
AZN Stock Performance
The stock underperformed the industry in the year-to-date period, as seen in the chart below.
Image Source: Zacks Investment Research
Other Players in the IgAN Space
If approved, Ultomiris will likely compete with Calliditas Therapeutics’ Tarpeyo, Novartis’ NVS Fabhalta and Travere Therapeutics’ TVTX Filspari.
Both Calliditas’ Tarpeyo and Travere’s Filspari are approved for a similar indication — slowing the decline in kidney function in adults with primary IgAN who are at risk of disease progression.
Novartis’ Fabhalta is approved under the accelerated pathway for reducing proteinuria in adults with primary IgAN who are at risk of rapid disease progression. The NVS drug is also approved for complement 3 glomerulopathy (C3G) and PNH indications.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpAstraZeneca PLC (AZN) : Free Stock Analysis Report
Novartis AG (NVS) : Free Stock Analysis Report
Travere Therapeutics, Inc. (TVTX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
